Abstract
Epithelial-mesenchymal transition (EMT) is a vital process implemented in embryo development, organ fibrosis, and cancer metastasis. Several transcription factors and signaling pathways impinge on the transcriptional program of the cell, leading to the change of cell phenotype without alteration of genotype. Accumulating evidence suggests that epigenetic mechanisms play important roles in inducing EMT and orchestrating the heredity and reversibility of EMT. In this review, we discuss how DNA methylation, histone modifications, and microRNAs (miRNAs) act in a concerted manner to regulate EMT. ‘Epigenetic therapies’—inhibitors of DNA methyltransferases and histone deacetylases as well as microRNAs are emerging as promising agents for cancer intervention.
Keywords: DNMT inhibitors, EMT, epigenetic regulation, epigenetic therapy, HDAC inhibitors, metastasis, miRNAs.
Current Cancer Drug Targets
Title:Epigenetic Regulation of Epithelial to Mesenchymal Transition
Volume: 13 Issue: 9
Author(s): Peiwei Huangyang and Yongfeng Shang
Affiliation:
Keywords: DNMT inhibitors, EMT, epigenetic regulation, epigenetic therapy, HDAC inhibitors, metastasis, miRNAs.
Abstract: Epithelial-mesenchymal transition (EMT) is a vital process implemented in embryo development, organ fibrosis, and cancer metastasis. Several transcription factors and signaling pathways impinge on the transcriptional program of the cell, leading to the change of cell phenotype without alteration of genotype. Accumulating evidence suggests that epigenetic mechanisms play important roles in inducing EMT and orchestrating the heredity and reversibility of EMT. In this review, we discuss how DNA methylation, histone modifications, and microRNAs (miRNAs) act in a concerted manner to regulate EMT. ‘Epigenetic therapies’—inhibitors of DNA methyltransferases and histone deacetylases as well as microRNAs are emerging as promising agents for cancer intervention.
Export Options
About this article
Cite this article as:
Huangyang Peiwei and Shang Yongfeng, Epigenetic Regulation of Epithelial to Mesenchymal Transition, Current Cancer Drug Targets 2013; 13 (9) . https://dx.doi.org/10.2174/15680096113136660103
DOI https://dx.doi.org/10.2174/15680096113136660103 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chinese Medicinal Herbs as Source of Antioxidant Compounds – Where Tradition Meets the Future
Current Medicinal Chemistry MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Targeting Prenylated RAS Modifying Enzymes in Cancer Cells
Current Signal Transduction Therapy Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Current Gene Therapy Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters NSAIDs and Chemoprevention
Current Cancer Drug Targets 5-Fluorouracil Derivatives Induce Differentiation Mediated by Tubulin and HLA Class I Modulation
Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer
Current Drug Research Reviews Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Evolving Novel Chemical Entities for Management of Benign Prostatic Hyperplasia#
Mini-Reviews in Medicinal Chemistry Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry Expression and Prognostic Significance of the MMP Family Molecules in Bladder Cancer
Combinatorial Chemistry & High Throughput Screening Tachykinins and the Cardiovascular System
Current Drug Targets